Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash from Financing Activities (2020 - 2025)

Arcutis Biotherapeutics has reported Cash from Financing Activities over the past 6 years, most recently at $3.7 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $3.7 million for Q4 2025, up 103.82% from a year ago — trailing twelve months through Dec 2025 was $7.0 million (down 89.47% YoY), and the annual figure for FY2025 was $7.0 million, down 89.47%.
  • Cash from Financing Activities for Q4 2025 was $3.7 million at Arcutis Biotherapeutics, up from $1.5 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for ARQT hit a ceiling of $285.0 million in Q3 2022 and a floor of -$97.4 million in Q4 2024.
  • Median Cash from Financing Activities over the past 5 years was $1.3 million (2021), compared with a mean of $37.9 million.
  • Biggest five-year swings in Cash from Financing Activities: soared 452263.49% in 2022 and later crashed 198.11% in 2024.
  • Arcutis Biotherapeutics' Cash from Financing Activities stood at $72.9 million in 2021, then plummeted by 98.68% to $962000.0 in 2022, then skyrocketed by 10221.1% to $99.3 million in 2023, then crashed by 198.11% to -$97.4 million in 2024, then surged by 103.82% to $3.7 million in 2025.
  • The last three reported values for Cash from Financing Activities were $3.7 million (Q4 2025), $1.5 million (Q3 2025), and $1.4 million (Q2 2025) per Business Quant data.